Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01622088 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Extension Study of Dexpramipexole in ALS
A Phase 3 study, sponsored by Knopp Biosciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 616
- Enrollment target
NCT01622088 is a Phase 3 study that was terminated before completion, run by Knopp Biosciences. The registered enrollment target is 616 participants.
The verdict
NCT01622088, a Phase 3 study, was terminated before completion, sponsored by Knopp Biosciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 616 participants
- Enrollment target
Study Summary
The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.
Interventions
- DRUG Dexpramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 616 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01622088
The ClinicalTrials.gov registry entry for NCT01622088 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 616 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexpramipexole is the first listed.
NCT01622088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01622088 about?
NCT01622088 is a clinical study titled "Phase 3 Extension Study of Dexpramipexole in ALS". The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.
What is the current status of trial NCT01622088?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 616 participants. The study started on 2012-06. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01622088?
The interventions under investigation include: Dexpramipexole (DRUG).
Who is sponsoring clinical trial NCT01622088?
This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.